Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Effectiveness of Sacubitril/Valsartan in real-life practice: experience of a single center
Session:
Posters 5 - Écran 05 - IC - Terapêutica
Speaker:
Joana P. Neiva
Congress:
CPC 2018
Topic:
D. Heart Failure
Theme:
10. Chronic Heart Failure
Subtheme:
10.4 Chronic Heart Failure – Treatment
Session Type:
Posters
FP Number:
---
Authors:
Joana P. Neiva; Inés Gómez Otero; Alfonso Varela-Roman; Ana Seoane Blanco; María Moure Gonzalez; Jose Ramon Juanatey
Abstract
<p>Introduction: Sacubitril/valsartan (SV) reduced mortality and hospitalizations in the PARADIGM-HF trial as compared to enalapril in patients (P) with chronic heart failure with reduced ejection fraction (HFrEF). ESC guidelines currently recommend SV for P with ongoing symptomatic HFrEF, despite first line medical therapy.</p> <p>Purpose: Evaluate effectiveness of SV, regarding impact on functional capacity and on HF related outcomes and healthcare resource utilization.</p> <p>Methods: Retrospective and descriptive study extended to all P on SV in a specialized HF unit in a single center since October 2016. Demographics, medical history, concomitant treatment and final dose were analyzed. Clinical parameters such as functional class of New York Heart Association (NYHA) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were assessed at each evaluation. Outcomes assessed were: HF hospitalization, non-elective hospitalization for any reason; death for any cause; cardiovascular (CV) death and emergency department (ED) visits due to decompensated HF. Descriptive statistics and Kaplan-Meier curve were used for analysis.</p> <p>Results: Within a population of 106P (79% male; 68,2+10,7 years; 45,3% ischemic etiology; mean left ventricular ejection fraction (LVEF) 29,5%), 75,5% had NYHA II and 23,6% NYHA III at baseline. Mean baseline NT-proBNP was 2415pg/mL. 99,1% of P were on ACEI/ARB, 98,1% with beta-blockers and 89,6% on MRA. 52,8% had implantable cardioverter defibrillator and 31,1% cardiac resynchronization therapy system. The mean follow-up time was 194 days (4 – 421). Up-titration to maximum dose was achieved in 45,3%. 41,5%P had subjective improvement in symptoms and quality of life. NYHA class improved in 35,5%P (2P upgraded two classes); in 25,3%P it occurred early on first month. NT-proBNP did not significantly change (2415 vs 2104pg/mL). The mortality rate was 2,8% - all 3P had sudden death, HF hospitalization occurred in 2,8% (3P), hospitalization for all reasons in 6,6% (42,8% for non CV etiologies) and 2,8% (3P) had ED visits due to acute HF. Of 13P who obtained repeated LVEF measurement, 8 (61,5%) had improved LVEF (increase of 8,3%).</p> <p>Conclusion: Our data suggests that SV is effectiveness in real-life. The overall outcomes rates were lower when compared to PARADIGM-HF trial, however our mean follow-up period was significantly shorter and our population is monitored closely in an HF specialized consultation.</p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site